このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Glenmark Pharmaceuticals 配当金
配当金 基準チェック /26
Glenmark Pharmaceuticals配当を支払う会社であり、現在の利回りは0.2%です。
主要情報
0.2%
配当利回り
-4%
配当性向
| 業界平均利回り | 0.7% |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | ₹2.500 |
| 一株当たり利益 | -₹67.30 |
| 3年後の配当利回り予想 | 0.2% |
最近の配当金アップデート
Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17
Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30Recent updates
Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Jan 18We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Dec 13決済の安定と成長
配当データの取得
安定した配当: GLENMARKの1株当たり配当金は過去10年間安定しています。
増加する配当: GLENMARKの配当金は過去10年間にわたって増加しています。
配当利回り対市場
| Glenmark Pharmaceuticals 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (GLENMARK) | 0.2% |
| 市場下位25% (IN) | 0.3% |
| 市場トップ25% (IN) | 1.1% |
| 業界平均 (Pharmaceuticals) | 0.7% |
| 3年後のアナリスト予想 (GLENMARK) | 0.2% |
注目すべき配当: GLENMARKの配当金 ( 0.2% ) はIndian市場の配当金支払者の下位 25% ( 0.27% ) と比べると目立ったものではありません。
高配当: GLENMARKの配当金 ( 0.2% ) はIndian市場の配当金支払者の上位 25% ( 1.16% ) と比較すると低いです。
株主への利益配当
収益カバレッジ: GLENMARKは配当金を支払っていますが、会社は利益を上げていません。
株主配当金
キャッシュフローカバレッジ: GLENMARKは配当金を支払っていますが、同社にはフリーキャッシュフローがありません。